{"pmid":32471278,"title":"Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.","text":["Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.","At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses. COVID-19 pathology is characterized by extreme inflammation and amplified immune response with activation of a cytokine storm. A subsequent progression to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) can take place, which is often followed by death. The causes of these strong inflammatory responses in SARS-CoV-2 infection are still unknown. As uncontrolled pulmonary inflammation is likely the main cause of death in SARS-CoV-2 infection, anti-inflammatory therapeutic interventions are particularly important. Fenretinide N-(4-hydroxyphenyl) retinamide is a bioactive molecule characterized by poly-pharmacological properties and a low toxicity profile. Fenretinide is endowed with antitumor, anti-inflammatory, antiviral, and immunomodulating properties other than efficacy in obesity/diabetic pathologies. Its anti-inflammatory and antiviral activities, in particular, could likely have utility in multimodal therapies for the treatment of ALI/ARDS in COVID-19 patients. Moreover, fenretinide administration by pulmonary delivery systems could further increase its therapeutic value by carrying high drug concentrations to the lungs and triggering a rapid onset of activity. This is particularly important in SARS-CoV-2 infection, where only a narrow time window exists for therapeutic intervention.","Int J Mol Sci","Orienti, Isabella","Gentilomi, Giovanna Angela","Farruggia, Giovanna","32471278"],"abstract":["At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses. COVID-19 pathology is characterized by extreme inflammation and amplified immune response with activation of a cytokine storm. A subsequent progression to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) can take place, which is often followed by death. The causes of these strong inflammatory responses in SARS-CoV-2 infection are still unknown. As uncontrolled pulmonary inflammation is likely the main cause of death in SARS-CoV-2 infection, anti-inflammatory therapeutic interventions are particularly important. Fenretinide N-(4-hydroxyphenyl) retinamide is a bioactive molecule characterized by poly-pharmacological properties and a low toxicity profile. Fenretinide is endowed with antitumor, anti-inflammatory, antiviral, and immunomodulating properties other than efficacy in obesity/diabetic pathologies. Its anti-inflammatory and antiviral activities, in particular, could likely have utility in multimodal therapies for the treatment of ALI/ARDS in COVID-19 patients. Moreover, fenretinide administration by pulmonary delivery systems could further increase its therapeutic value by carrying high drug concentrations to the lungs and triggering a rapid onset of activity. This is particularly important in SARS-CoV-2 infection, where only a narrow time window exists for therapeutic intervention."],"journal":"Int J Mol Sci","authors":["Orienti, Isabella","Gentilomi, Giovanna Angela","Farruggia, Giovanna"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471278","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/ijms21113812","keywords":["covid-19","adjuvant treatment","anti-inflammatory","antiviral environment","fenretinide","pulmonary delivery"],"topics":["Treatment"],"weight":1,"_version_":1668255193274253313,"score":9.490897,"similar":[{"pmid":32217117,"pmcid":"PMC7102583","title":"COVID-19: Melatonin as a potential adjuvant treatment.","text":["COVID-19: Melatonin as a potential adjuvant treatment.","This article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis. The recent outbreak of COVID-19 has become a pandemic with tens of thousands of infected patients. Based on clinical features, pathology, the pathogenesis of acute respiratory disorder induced by either highly homogenous coronaviruses or other pathogens, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response very likely contribute to COVID-19 pathology. This leads to a cytokine storm and subsequent progression to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and often death. Melatonin, a well-known anti-inflammatory and anti-oxidative molecule, is protective against ALI/ARDS caused by viral and other pathogens. Melatonin is effective in critical care patients by reducing vessel permeability, anxiety, sedation use, and improving sleeping quality, which might also be beneficial for better clinical outcomes for COVID-19 patients. Notably, melatonin has a high safety profile. There is significant data showing that melatonin limits virus-related diseases and would also likely be beneficial in COVID-19 patients. Additional experiments and clinical studies are required to confirm this speculation.","Life Sci","Zhang, Rui","Wang, Xuebin","Ni, Leng","Di, Xiao","Ma, Baitao","Niu, Shuai","Liu, Changwei","Reiter, Russel J","32217117"],"abstract":["This article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis. The recent outbreak of COVID-19 has become a pandemic with tens of thousands of infected patients. Based on clinical features, pathology, the pathogenesis of acute respiratory disorder induced by either highly homogenous coronaviruses or other pathogens, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response very likely contribute to COVID-19 pathology. This leads to a cytokine storm and subsequent progression to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and often death. Melatonin, a well-known anti-inflammatory and anti-oxidative molecule, is protective against ALI/ARDS caused by viral and other pathogens. Melatonin is effective in critical care patients by reducing vessel permeability, anxiety, sedation use, and improving sleeping quality, which might also be beneficial for better clinical outcomes for COVID-19 patients. Notably, melatonin has a high safety profile. There is significant data showing that melatonin limits virus-related diseases and would also likely be beneficial in COVID-19 patients. Additional experiments and clinical studies are required to confirm this speculation."],"journal":"Life Sci","authors":["Zhang, Rui","Wang, Xuebin","Ni, Leng","Di, Xiao","Ma, Baitao","Niu, Shuai","Liu, Changwei","Reiter, Russel J"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32217117","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.lfs.2020.117583","keywords":["covid-19","cytokines","immunomodulation","melatonin","oxidation-reduction","sars-cov-2"],"e_drugs":["Melatonin"],"topics":["Treatment"],"weight":1,"_version_":1666138492316418048,"score":322.70273},{"pmid":32376394,"title":"Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.","text":["Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.","Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called \"cytokine storm\". The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and clot activation must also be considered. Furthermore, we must keep in mind that currently, no specific antiviral treatment is available for SARS-CoV-2. While moderate-severe forms need in-hospital surveillance plus antivirals and/or hydroxychloroquine; in severe and life-threating subsets a high intensity anti-inflammatory and immunomodulatory therapy could be a therapeutic option. However, right data on the effectiveness of different immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs such as: antimalarials, anti-IL6, anti-IL-1, calcineurin and JAK inhibitors, corticosteroids, immunoglobulins, heparins, angiotensin-converting enzyme agonists and statins in severe COVID-19.","Autoimmun Rev","Alijotas-Reig, Jaume","Esteve-Valverde, Enrique","Belizna, Cristina","Selva-O'Callaghan, Albert","Pardos-Gea, Josep","Quintana, Angela","Mekinian, Arsene","Anunciacion-Lunell, Ariadna","Miro-Mur, Francesc","32376394"],"abstract":["Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called \"cytokine storm\". The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and clot activation must also be considered. Furthermore, we must keep in mind that currently, no specific antiviral treatment is available for SARS-CoV-2. While moderate-severe forms need in-hospital surveillance plus antivirals and/or hydroxychloroquine; in severe and life-threating subsets a high intensity anti-inflammatory and immunomodulatory therapy could be a therapeutic option. However, right data on the effectiveness of different immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs such as: antimalarials, anti-IL6, anti-IL-1, calcineurin and JAK inhibitors, corticosteroids, immunoglobulins, heparins, angiotensin-converting enzyme agonists and statins in severe COVID-19."],"journal":"Autoimmun Rev","authors":["Alijotas-Reig, Jaume","Esteve-Valverde, Enrique","Belizna, Cristina","Selva-O'Callaghan, Albert","Pardos-Gea, Josep","Quintana, Angela","Mekinian, Arsene","Anunciacion-Lunell, Ariadna","Miro-Mur, Francesc"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376394","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102569","keywords":["acute respiratory distress syndrome","covid-19","cytokine storm","immunosuppressive","sars-cov-2","treatment"],"e_drugs":["Hydroxychloroquine","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666597097290334208,"score":255.20834},{"pmid":32385712,"title":"Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?","text":["Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?","Severe coronavirus disease (COVID-19) is characterized by pulmonary hyper-inflammation and potentially life-threatening \"cytokine storms\". Controlling the local and systemic inflammatory response in COVID-19 may be as important as anti-viral therapies. Endogenous lipid autacoid mediators, referred to as eicosanoids, play a critical role in the induction of inflammation and pro-inflammatory cytokine production. SARS-CoV-2 may trigger a cell death (\"debris\")-induced \"eicosanoid storm\", including prostaglandins and leukotrienes, which in turn initiates a robust inflammatory response. A paradigm shift is emerging in our understanding of the resolution of inflammation as an active biochemical process with the discovery of novel endogenous specialized pro-resolving lipid autacoid mediators (SPMs), such as resolvins. Resolvins and other SPMs stimulate macrophage-mediated clearance of debris and counter pro-inflammatory cytokine production, a process called inflammation resolution. SPMs and their lipid precursors exhibit anti-viral activity at nanogram doses in the setting of influenza without being immunosuppressive. SPMs also promote anti-viral B cell antibodies and lymphocyte activity, highlighting their potential use in the treatment of COVID-19. Soluble epoxide hydrolase (sEH) inhibitors stabilize arachidonic acid-derived epoxyeicosatrienoic acids (EETs), which also stimulate inflammation resolution by promoting the production of pro-resolution mediators, activating anti-inflammatory processes, and preventing the cytokine storm. Both resolvins and EETs also attenuate pathological thrombosis and promote clot removal, which is emerging as a key pathology of COVID-19 infection. Thus, both SPMs and sEH inhibitors may promote the resolution of inflammation in COVID-19, thereby reducing acute respiratory distress syndrome (ARDS) and other life-threatening complications associated with robust viral-induced inflammation. While most COVID-19 clinical trials focus on \"anti-viral\" and \"anti-inflammatory\" strategies, stimulating inflammation resolution is a novel host-centric therapeutic avenue. Importantly, SPMs and sEH inhibitors are currently in clinical trials for other inflammatory diseases and could be rapidly translated for the management of COVID-19 via debris clearance and inflammatory cytokine suppression. Here, we discuss using pro-resolution mediators as a potential complement to current anti-viral strategies for COVID-19.","Cancer Metastasis Rev","Panigrahy, Dipak","Gilligan, Molly M","Huang, Sui","Gartung, Allison","Cortes-Puch, Irene","Sime, Patricia J","Phipps, Richard P","Serhan, Charles N","Hammock, Bruce D","32385712"],"abstract":["Severe coronavirus disease (COVID-19) is characterized by pulmonary hyper-inflammation and potentially life-threatening \"cytokine storms\". Controlling the local and systemic inflammatory response in COVID-19 may be as important as anti-viral therapies. Endogenous lipid autacoid mediators, referred to as eicosanoids, play a critical role in the induction of inflammation and pro-inflammatory cytokine production. SARS-CoV-2 may trigger a cell death (\"debris\")-induced \"eicosanoid storm\", including prostaglandins and leukotrienes, which in turn initiates a robust inflammatory response. A paradigm shift is emerging in our understanding of the resolution of inflammation as an active biochemical process with the discovery of novel endogenous specialized pro-resolving lipid autacoid mediators (SPMs), such as resolvins. Resolvins and other SPMs stimulate macrophage-mediated clearance of debris and counter pro-inflammatory cytokine production, a process called inflammation resolution. SPMs and their lipid precursors exhibit anti-viral activity at nanogram doses in the setting of influenza without being immunosuppressive. SPMs also promote anti-viral B cell antibodies and lymphocyte activity, highlighting their potential use in the treatment of COVID-19. Soluble epoxide hydrolase (sEH) inhibitors stabilize arachidonic acid-derived epoxyeicosatrienoic acids (EETs), which also stimulate inflammation resolution by promoting the production of pro-resolution mediators, activating anti-inflammatory processes, and preventing the cytokine storm. Both resolvins and EETs also attenuate pathological thrombosis and promote clot removal, which is emerging as a key pathology of COVID-19 infection. Thus, both SPMs and sEH inhibitors may promote the resolution of inflammation in COVID-19, thereby reducing acute respiratory distress syndrome (ARDS) and other life-threatening complications associated with robust viral-induced inflammation. While most COVID-19 clinical trials focus on \"anti-viral\" and \"anti-inflammatory\" strategies, stimulating inflammation resolution is a novel host-centric therapeutic avenue. Importantly, SPMs and sEH inhibitors are currently in clinical trials for other inflammatory diseases and could be rapidly translated for the management of COVID-19 via debris clearance and inflammatory cytokine suppression. Here, we discuss using pro-resolution mediators as a potential complement to current anti-viral strategies for COVID-19."],"journal":"Cancer Metastasis Rev","authors":["Panigrahy, Dipak","Gilligan, Molly M","Huang, Sui","Gartung, Allison","Cortes-Puch, Irene","Sime, Patricia J","Phipps, Richard P","Serhan, Charles N","Hammock, Bruce D"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32385712","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s10555-020-09889-4","keywords":["covid-19","cytokine storms","eicosanoid storm","inflammation resolution","sars-cov-2"],"e_drugs":["Eicosanoids","Arachidonic Acid","Lipids","Prostaglandins","Leukotrienes"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666340102065881089,"score":253.19237},{"pmid":32366290,"pmcid":"PMC7197031","title":"Mesenchymal stem cells as a potential therapy for COVID-19.","text":["Mesenchymal stem cells as a potential therapy for COVID-19.","The outbreak of 2019 novel coronavirus disease (COVID-19) worldwide is becoming rapidly a major concern. The number of severe cases has increased dramatically worldwide, while specific treatment options are scarce. The main pathologic features of severe or critical COVID-19 were consistent with acute lung injure (ALI)/acute respiratory distress syndrome (ARDS), characterized by cellular fibromyxoid exudates, extensive pulmonary inflammation, pulmonary edema, and hyaline membrane formation. Mesenchymal stem cells (MSCs) can balance the inflammatory response and has been mentioned to be effective on ALI/ARDS from both infectious and noninfectious causes previously, presenting an important opportunity to be applied to COVID-19. In this commentary, we summarize the clinical trials of MSCs treatments on ALI/ARDS and raise MSCs as a hopefully alternative therapy for severe or critical COVID-19.","Stem Cell Res Ther","Liu, Shan","Peng, Danyi","Qiu, Huijun","Yang, Ke","Fu, Zhou","Zou, Lin","32366290"],"abstract":["The outbreak of 2019 novel coronavirus disease (COVID-19) worldwide is becoming rapidly a major concern. The number of severe cases has increased dramatically worldwide, while specific treatment options are scarce. The main pathologic features of severe or critical COVID-19 were consistent with acute lung injure (ALI)/acute respiratory distress syndrome (ARDS), characterized by cellular fibromyxoid exudates, extensive pulmonary inflammation, pulmonary edema, and hyaline membrane formation. Mesenchymal stem cells (MSCs) can balance the inflammatory response and has been mentioned to be effective on ALI/ARDS from both infectious and noninfectious causes previously, presenting an important opportunity to be applied to COVID-19. In this commentary, we summarize the clinical trials of MSCs treatments on ALI/ARDS and raise MSCs as a hopefully alternative therapy for severe or critical COVID-19."],"journal":"Stem Cell Res Ther","authors":["Liu, Shan","Peng, Danyi","Qiu, Huijun","Yang, Ke","Fu, Zhou","Zou, Lin"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32366290","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1186/s13287-020-01678-8","keywords":["ali","ards","covid-19","mscs"],"topics":["Treatment"],"weight":1,"_version_":1666138496178323456,"score":249.68431},{"pmid":32471272,"title":"Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?","text":["Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?","In late December 2019, a novel coronavirus (SARS-CoV-2 or CoV-19) appeared in Wuhan, China, causing a global pandemic. SARS-CoV-2 causes mild to severe respiratory tract inflammation, often developing into lung fibrosis with thrombosis in pulmonary small vessels and causing even death. COronaVIrus Disease (COVID-19) patients manifest exacerbated inflammatory and immune responses, cytokine storm, prevalence of pro-inflammatory M1 macrophages and increased levels of resident and circulating immune cells. Men show higher susceptibility to SARS-CoV-2 infection than women, likely due to estrogens production. The protective role of&nbsp;estrogens, as well as an immune-suppressive activity that limits the excessive inflammation, can be mediated by cannabinoid receptor type 2 (CB2). The role of this receptor in modulating inflammation and immune response is well documented in fact in several settings. The stimulation of CB2 receptors is known to limit the release of pro-inflammatory cytokines, shift the macrophage phenotype towards the anti-inflammatory M2 type and enhance the immune-modulating properties of mesenchymal stromal cells. For these reasons, we hypothesize that CB2 receptor can be a therapeutic target in COVID-19 pandemic emergency.","Int J Mol Sci","Rossi, Francesca","Tortora, Chiara","Argenziano, Maura","Di Paola, Alessandra","Punzo, Francesca","32471272"],"abstract":["In late December 2019, a novel coronavirus (SARS-CoV-2 or CoV-19) appeared in Wuhan, China, causing a global pandemic. SARS-CoV-2 causes mild to severe respiratory tract inflammation, often developing into lung fibrosis with thrombosis in pulmonary small vessels and causing even death. COronaVIrus Disease (COVID-19) patients manifest exacerbated inflammatory and immune responses, cytokine storm, prevalence of pro-inflammatory M1 macrophages and increased levels of resident and circulating immune cells. Men show higher susceptibility to SARS-CoV-2 infection than women, likely due to estrogens production. The protective role of&nbsp;estrogens, as well as an immune-suppressive activity that limits the excessive inflammation, can be mediated by cannabinoid receptor type 2 (CB2). The role of this receptor in modulating inflammation and immune response is well documented in fact in several settings. The stimulation of CB2 receptors is known to limit the release of pro-inflammatory cytokines, shift the macrophage phenotype towards the anti-inflammatory M2 type and enhance the immune-modulating properties of mesenchymal stromal cells. For these reasons, we hypothesize that CB2 receptor can be a therapeutic target in COVID-19 pandemic emergency."],"journal":"Int J Mol Sci","authors":["Rossi, Francesca","Tortora, Chiara","Argenziano, Maura","Di Paola, Alessandra","Punzo, Francesca"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471272","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/ijms21113809","keywords":["covid-19","sars-cov-2","cannabinoid receptor type 2","endocannabinoids system","immune response","inflammation","molecular target","therapeutic strategies"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668255193299419136,"score":247.87805}]}